Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51

Abstract Japanese encephalitis (JE) is the most common viral encephalitis in Asia. IC51 is a new Vero cell-derived, inactivated JE virus vaccine with non-inferior immunogenicity (after 2 months) compared to the US-licensed vaccine JE-VAX® (mouse brain-derived, inactivated) and with a more convenient...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2008, Vol.26 (34), p.4382-4386
Main Authors: Schuller, E, Jilma, B, Voicu, V, Golor, G, Kollaritsch, H, Kaltenböck, A, Klade, C, Tauber, E
Format: Article
Language:English
Subjects:
Allergy and Immunology
Japanese encephalitis
Vaccine
Virus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Japanese encephalitis (JE) is the most common viral encephalitis in Asia. IC51 is a new Vero cell-derived, inactivated JE virus vaccine with non-inferior immunogenicity (after 2 months) compared to the US-licensed vaccine JE-VAX® (mouse brain-derived, inactivated) and with a more convenient (two injections instead of three) intramuscular dose schedule. Adult subjects from two studies were followed-up for comparative immunogenicity (JE-VAX® ) at 6 months and long-term immunogenicity of IC51 alone at 12 months. At 6 months, immunogenicity was higher with IC51 (seroconversion rate [SCR] 95%; geometric mean titer [GMT] 84) than with JE-VAX® (SCR 74%; GMT 34). At 12 months, the SCR was 83% and the GMT (41) remained above the protective titer of 1:10. Most people immunized with IC51 will have protective neutralizing antibody levels for at least a year.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2008.05.081